Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 939-946

  Petrangolini, Giovanna ^a   Supino, Rosanna ^a   Pratesi, Graziella ^a   Dal Bo, Laura ^a   Tortoreto, Monica ^a   Croce, Anna Cleta ^b   Misiano, Paola ^c   Belfiore, Pietro ^c,d   Farina, Carlo ^c   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c NiKem Research   (Italy)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; [4-(5,6 DICHLORO 1H INDOL 2 YL) 3 ETHOXY N (2,2,6,6 TETRAMETHYL PIPERIDIN 4 YL) BENZAMIDEL; ADENOSINE TRIPHOSPHATASE INHIBITOR; BAFILOMYCIN A1; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; DNA TOPOISOMERASE; GLYCOPROTEIN P; INDOLE DERIVATIVE; PROTON; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL STRAIN HT29; CELLULAR DISTRIBUTION; CHEMICAL STRUCTURE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HYPOXIC CELL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STAINING; TONOPLAST; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZAMIDES; CAMPTOTHECIN; ENZYME INHIBITORS; FEMALE; HT29 CELLS; HUMANS; INDOLES; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; STAINING AND LABELING; TOPOTECAN; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 33747600900     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.103481     Document Type: Article

References (40)

1. Adams DJ, Wahl ML, Flowers JL, Sem B, Colvin M, Dewhirst MW, Manikumar G, and Wani MC (2006) Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother Pharmacol 57:145-154.
2. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93-141.
3. Beutler JA and McKee TC (2003) Novel marine and microbial natural product inhibitors of vacuolar ATPase. Curr Med Chem 10:787-796.
4. Bowman EJ, Gustafson KR, Bowman BJ, and Boyd MR (2003) Identification of a new chondropsin class of antitumor compound that selectively inhibits V-APTases. J Biol Chem 278:44147-44152.
5. Bowman EJ, Siebers A, and Altendorf K (1988) Bafilomycins: a class of inhibitors of membrane ATPase from microorganisms, animal cells and plant cells. Proc Natl Acad Sci USA 85:7972-7976.
6. +)-ATPases. J Pharmacol Exp Ther 297:114-120.
7. Croce AC, Bottiroli G, Supino R, Favini E, Zuco V, and Zunino F (2004) Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol 67:1035-1045.
8. +-ATPase. Curr Pharm Des 8:2033-2048.
9. +-ATPase. Farmaco 56:113-116.
10. Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, and Adams DJ (2003) The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemother Pharmacol 52:253-261.
11. +-ATPase. Curr Med Chem 6:1197-1212.
12. Glavinas H, Krajcsi P, Cserepes J, and Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27-42.
13. Grandi M, Geroni C, and Giuliani FC (1986) Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer 54:515-518.
14. Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H, Ingenhorst G, Zeeck A, and Wieczorek H (2005) Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochemistry 6:13-22.
15. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M, et al. (2003) Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 29:541-549.
16. Larsen AK, Escargueil AE, and Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217-229.
17. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, et al. (2004) Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 96:1702-1713.
18. 1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur J Cancer 39:532-540.
19. Montcourrier P, Mangeat PH, Valembois C, Salazar G, Sahuquet A, Duperray C, and Rochefort H (1994) Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J Cell Sci 107:2381-2391.
20. Nadler G, Morvan M, Delimoge I, Belfiore P, Zocchetti A, James I, Zembryki D, Lee-Rycakzewski E, Parmi C, Consolandi E, et al. (1998) (2Z,4E)-5-(5,6-Dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin- 4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase. Bioorg Med Chem Lett 8:3621-3626.
21. Niikura K, Takano M, and Sawada M (2004) A novel inhibitor of vacuolar ATPase, FRI167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol 142:558-566.
22. +)-ATPases: nature's most versatile proton pumps. Nat Rev Mol Cell Biol 3:94-103.
23. +-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J 370:185-193.
24. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D, and Yahalom J (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61:439-444.
25. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, et al. (2001) A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61:6034-6037.
26. Pratesi G, Manzotti C, Tortoreto M, Prosperi E, and Zunino F (1989) Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts. Tumori 75:60-65.
27. Putnam RW (2001) Intracellular pH regulation, in Cell Physiology Source-Book: A Molecular Approach (Sperelakis N ed) 3rd ed, pp 357-376, Academic Press, San Diego.
28. Raghunand N and Gillies RJ (2000) pH and drug resistance in tumors. Drug Resist Updat 3:39-47.
29. +-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol 286:C1443-C1452.
30. Simon S, Roy D, and Schindler M (1994) Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 91:1128-1132.
31. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
32. +-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem 277:36534-36543.
33. Traganos P and Darzynkiewicz Z (1994) Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocytes subpopulations, in Methods in Cell Biology:Flow Cytometry (Darzynkiewicz Z, Robinson JP, and Crissman HA eds) vol 41, pp 185-194, Academic Press, New York.
34. Vaupel P, Kallinowski F, and Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: review. Cancer Res 49:6449-6465.
35. Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M, and Farina C (2000) A selective inhibitor of the osteoclastic V-H+-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Investig 106:309-318.
36. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, et al. (1998) United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental Neoplasia (second edition). Br J Cancer 77:1-10.
37. Yeo M, Kim D-K, Kim YB, Oh TY, Lee JE, Cho SW, Kim HC, and Hahm KB (2004) Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 10:8687-8696.
38. Zanchi C, Zuco V, Lanzi C, Supino R, and Zunino F (2005) Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer Res 65:2364-2372.
39. Zuco V, Zanchi C, Cassinelli G, Lanzi C, Supino R, Pisano C, Zanier R, Giordano V, Garattine E, and Zunino F (2004) Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid. Cell Death Differ 11:280-289.
40. Zunino F and Pratesi G (2004) Camptothecins in clinical development. Expert Opin Investig Drugs 13:269-284.